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We read with great interest the paper “Heparin-Induced
Thrombocytopenia in Cardiac Surgery Patients” by Pishko
and Cuker1 and we found it very important with a view to
clinical prevention. The authors reviewed the epidemiology,
clinical diagnosis, and laboratory diagnosis of heparin-
induced thrombocytopenia (HIT) in cardiac surgery patients
and present a conceptual framework for selecting intrao-
perative anticoagulation in patients with a history of HIT.
With reference to the findings reported in the paper, we
would like to make the following contribution to the discus-
sion. We retrospectively analyzed data from 600 postcardiac
surgery patients to evaluate the incremental value of per-
forming 4Ts test and EuroSCORE (European System for
Cardiac Operative Risk Evaluation) test in identifying
patients at a high risk of developing anti-PF4/heparin anti-
bodies and thrombotic complications. A secondary end point
was thrombotic events during the 30-day follow-up.
Anti-PF4/heparin antibodies were tested in all patients
using a commercial immunoassay (Asserachrom Human PF4
ELISA [enzyme-linked immunosorbent assay] kits).2–4 No
functional HIT assay was performed. Preoperative ELISA
HIT testing was not performed. Of the 600 patients investi-
gated, 131 (21.8%) were found to have anti-PF4/heparin
antibodies in the postoperative period (5–7 days from sur-
gery). This group included both patients who were seropo-
sitive prior to surgery and those who seroconverted after
surgery. This is a limitation of the study. A previous systema-
tic review found that preoperative antibodies were present
in 5 to 22% of cardiac surgery patients.5Wecalculated the 4Ts
score and the EuroSCORE for our patient cohort6 using
scoring as previously reported.7,8 A high-probability 4Ts
score was predictive of anti-PF4/heparin antibody formation
and thrombotic events (►Table 16). The EuroSCORE did not
add any more information in our cohort of patients
(►Table 1). The only parameter of the EuroSCORE that added
information for stratificationwas the left ventricular ejection
fraction (►Table 2). Reduced ejection fraction is a marker of
severity of cardiac disease and is associated with an
increased risk of thrombosis.9 Patients with reduced ejection
fraction may be more likely to have been treated with
heparin, which might favor the development of anti PF4/
heparin antibodies in cardiac surgery patients preopera-
tively leading to possible “early onset” HIT.10 This is a rare
form of HIT characterized by early onset of thrombocytope-
nia, a confounding factor in patients undergoing cardiac
surgery.10 In fact, in cardiac surgery patients, early onset
and persisting thrombocytopenia can be explained by sev-
eral non-HIT factors (e.g., postoperative multiorgan system
failure).10 Patients with a high probability 4Ts test and a
reduced ejection fraction therefore need a more careful
evaluation. In these patients, a test for anti-PF4/heparin
antibodies would be useful to enable early diagnosis of HIT
and, consequently, enable better management of anticoagu-
lant therapy in patients found to have pathological HIT.
Patients with HIT are at a high risk of thrombosis, and
when pathological HIT is strongly suspected or confirmed,
heparin should be stopped according to the American Col-
lege of Chest Physicians guidelines.9 Furthermore, appropri-
ate alternative anticoagulant therapy should be promptly
initiated at therapeutic doses until the platelet count has
recovered.
In patients with intermediate-to-high likelihood of com-
plications, as predicted by EuroSCORE, the addition of 4Ts
score improved the prediction of events (►Table 1). These
patients need a more careful follow-up, and immunological
tests for anti-PF4/heparin antibodies, followed by functional
HIT confirmation, could help prevent thrombotic complica-
tions related to pathological HIT.2–5,7–9,11,12 We agree with
Pishko and Cuker that it is necessary to distinguish the
common platelet count fall associated with CPB and surgery
from the much less common platelet count fall associated
with HIT. The 4Ts score and the EuroSCORE might help to
identify high-risk patients that need close follow-up to avoid
thrombotic complications related to HIT.
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Table 1 Thrombotic events in patients stratified according 4Ts score and EuroSCORE
High score, n (%) Intermediate score, n (%) Low score, n (%)
4Ts score (n ¼ 131 patients) 57 (43.5%) 36 (27.4%) 9 (6.8%)
EuroSCORE (n ¼ 131 patients) 57 (43.5%) 33 (25.1%) 12 (9.1%)
Abbreviation: EuroSCORE, European System for Cardiac Operative Risk Evaluation.
Table 2 Association of thrombosis with 4Ts score in all patients who yielded intermediate and high 4Ts score, in patients with a
high EuroSCORE, and in patients with low ejection fraction
4Ts score
Low
(reference)
Intermediate, HR (95% CI) High, HR (95% CI)
Total population
(131 patients)
1 1.05 (0.76–1.01) 1.74 (0.9–2.2)a
Patients with a high EuroSCORE value (87 patients) 1 1.12 (0.34–1.15) 1.24 (0.42–1.56)
Patients with low ejection fraction
(55 patients)
1 0.98 (0.66–0.98) 2.0 (0.56–2.34)a
Abbreviations: CI, confidence interval; EuroSCORE, European System for Cardiac Operative Risk Evaluation; HR, hazard ratio.
ap < 0.05.
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